In an adult presenting with sudden dyspnea and a rapid, complete right‑hemithorax white‑out on chest X‑ray, what aggressive lymphoma is most likely, and what are the recommended diagnostic steps and first‑line treatment?

Aggressive Lymphoma Presenting as Acute Hemithorax White-Out

In an adult with sudden dyspnea and complete right hemithorax opacification, diffuse large B-cell lymphoma (DLBCL) is the most likely aggressive lymphoma, and you must obtain tissue diagnosis urgently via core needle biopsy while simultaneously initiating corticosteroid pre-phase treatment to prevent tumor lysis syndrome, followed by R-CHOP chemotherapy once diagnosis is confirmed.

Most Likely Diagnosis

DLBCL is the culprit here—it accounts for 30-58% of all non-Hodgkin lymphomas and is the most common aggressive lymphoma to present with rapid thoracic involvement 1, 2. While complete hemithorax white-out is unusual, case reports confirm that large cell lymphoma can replace lung parenchyma and cause this dramatic radiographic finding 3. The rapid onset of dyspnea with complete opacification suggests massive tumor burden, which is characteristic of aggressive B-cell lymphomas.

Immediate Diagnostic Steps

Emergency Tissue Acquisition

• Core needle biopsy is acceptable in emergency situations where the patient is too unstable for excisional biopsy 1
• Target the most accessible site—this could be pleural-based masses, mediastinal nodes, or even the lung mass itself
• If thoracentesis is performed for symptomatic relief, send pleural fluid for cytology and flow cytometry immediately 4

Critical Pitfall to Avoid

Do not delay biopsy waiting for bronchoscopy results—bronchoscopy frequently fails to reveal diagnostic material even when major airways appear involved 3. If bronchoscopy is non-diagnostic, proceed immediately to image-guided core biopsy or accessible lymph node biopsy.

Required Immunohistochemistry Panel

The pathologist must run at minimum 1, 2:

• CD45, CD20, CD3 (mandatory)
• CD10, BCL-2, BCL6, MUM1 (to determine germinal center vs. activated B-cell subtype)
• Ki-67 proliferation index

Staging Work-Up (Perform Concurrently)

While awaiting biopsy results, obtain 1, 2, 5:

• CT chest and abdomen (likely already done given presentation)
• Complete blood count and chemistry panel including LDH (critical prognostic marker) and uric acid (tumor lysis risk)
• HIV, Hepatitis B and C screening (mandatory)
• Bone marrow aspirate and biopsy
• PET scan to delineate full disease extent 5
• Cardiac function assessment (LVEF) before anthracycline therapy 1
• Consider lumbar puncture with prophylactic intrathecal chemotherapy if high-risk features present (elevated LDH, multiple extranodal sites) 1

Calculate the International Prognostic Index (IPI) and age-adjusted IPI immediately upon obtaining LDH and staging results 1, 2.

Pre-Treatment Emergency Management

Tumor Lysis Syndrome Prevention

Start corticosteroid pre-phase immediately if high tumor burden is evident (which it clearly is with complete hemithorax involvement) 1:

• Prednisone 100 mg PO daily for several days before chemotherapy 5
• Aggressive hydration
• Allopurinol or rasburicase
• Monitor electrolytes, renal function, and uric acid closely

This is non-negotiable—the massive tumor burden visible on imaging places this patient at extreme risk for tumor lysis syndrome.

First-Line Treatment

Standard R-CHOP Regimen

Once DLBCL is confirmed and CD20 positivity established, initiate 1, 2, 5:

For patients ≤60 years:

• 6-8 cycles of R-CHOP-21 (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone every 21 days)
• 8 total doses of rituximab

For patients 60-80 years:

• 8 cycles of R-CHOP-21 with 8 doses of rituximab 1, 5
• Alternative: 6 cycles R-CHOP-14 (every 14 days) with 8 rituximab doses

For patients >80 years:

• Consider R-mini-CHOP (attenuated doses) if comprehensive geriatric assessment shows frailty 5, 4

High-Risk Modifications

Given the massive presentation, this patient likely has high or high-intermediate IPI (aaIPI ≥2). In this scenario 1:

• CNS prophylaxis is mandatory—intrathecal methotrexate and/or cytarabine 1
• Consider enrollment in clinical trials for dose-intensified regimens
• Standard R-CHOP remains acceptable if clinical trials unavailable 1

Critical Treatment Principles

• Avoid dose reductions for hematological toxicity—use G-CSF support instead 1, 2
• Prophylactic G-CSF is justified for febrile neutropenia prevention in curative-intent treatment 1
• Radiotherapy to bulky sites has no proven benefit and should not be routinely added 1, 2

Response Evaluation Timeline

• Mid-treatment assessment: Repeat CT after 3-4 cycles 1
• End-of-treatment assessment: Repeat all abnormal baseline imaging 1
• PET scanning: If positive at baseline, use for response assessment per revised criteria 5
• Repeat bone marrow biopsy only if initially involved 1

Key Clinical Pearls

The combination of sudden dyspnea and complete hemithorax white-out demands immediate action—this represents life-threatening tumor burden. The differential includes massive pleural effusion, but the soft-tissue density on CT and rapid onset point toward aggressive lymphoma 3.

Do not be falsely reassured by negative bronchoscopy—parenchymal replacement by lymphoma often occurs without endobronchial lesions 3.

Age alone should not exclude aggressive treatment—even octogenarians can achieve complete remission with modified regimens 5, 4, though comprehensive geriatric assessment should guide intensity.

The prognosis depends heavily on achieving rapid diagnosis and initiating appropriate therapy. DLBCL is highly chemosensitive, and even patients with massive disease can achieve complete remission with R-CHOP 4, 6.